Matinas BioPharma, a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious and life-threatening diseases, has delivered positive updates on the safety and efficacy of its oral LNC-Docetaxel formulation. Notably, the company’s recent in vivo studies have shown remarkable results, demonstrating no evidence of weight loss even with a total administered dose over 8 times greater than the intravenous (IV) counterpart. Furthermore, Matinas BioPharma has made significant progress in its MAT2203 Compassionate/Expanded Use Access Program, with several patients experiencing complete clinical resolution from serious/life-threatening invasive fungal infections.
Incredible Safety Profile of Oral LNC-Docetaxel
The dosage comparison study between the oral LNC-Docetaxel formulation and IV-docetaxel has contributed encouraging results. Administered at a total dose exceeding 8 times that of the IV regimen, the oral LNC-Docetaxel has demonstrated a striking absence of weight loss. In contrast, patients receiving IV-docetaxel experienced an average peak weight loss of 20%.This discrepancy in weight loss highlights the potential of Matinas BioPharma’s oral LNC-Docetaxel formulation to mitigate adverse side effects commonly associated with the IV delivery method. Such findings exemplify the significance of this breakthrough formulation in enhancing patient quality of life during cancer treatment.
MAT2203 Compassionate Use Access Program
Expanding its portfolio of clinical programs, Matinas BioPharma has made considerable strides in its MAT2203 Compassionate/Expanded Use Access Program. This initiative aims to provide crucial therapeutic options for patients suffering from serious and life-threatening invasive fungal infections, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, coccidioidomycosis, and histoplasmosis.
Thus far, the enrollment of 19 patients in the program has displayed promising outcomes, with multiple patients experiencing complete clinical resolution. The positive responses exhibited by patients reflect the potential of MAT2203 to address the urgent need for effective treatments in this challenging medical domain.
FDA Agreement for Single Phase 3 Registration Trial
In yet another significant development, Matinas BioPharma has successfully reached an agreement with the U.S. Food and Drug Administration (FDA) for the design of a single Phase 3 registration trial to facilitate the preparation of a New Drug Application (NDA) for MAT2203. The trial, known as ORALTO, will primarily focus on evaluating the early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no alternative treatment options available.
This key FDA collaboration acknowledges the potential of Matinas BioPharma’s MAT2203 as an innovative therapy for addressing the urgent unmet medical needs of patients suffering from invasive aspergillosis. The decision to proceed with a single Phase 3 trial presents an efficient path towards regulatory approval, allowing for expedited patient access to this groundbreaking treatment option.
Conclusion:
Matinas BioPharma continues to make remarkable strides in the development of its oral LNC-Docetaxel formulation and the advancement of its MAT2203 program. The recent positive in vivo safety data, combined with the impressive clinical outcomes observed in the Compassionate/Expanded Use Access Program, provide a strong foundation for future advancements in these therapeutic areas. With a single Phase 3 registration trial agreement secured with the FDA for invasive aspergillosis treatment, Matinas BioPharma remains at the forefront of innovation in addressing critical medical needs.
Comments